Health Care & Life Sciences » Pharmaceuticals | Dicerna Pharmaceuticals Inc.

Dicerna Pharmaceuticals Inc. | Ownership

Companies that own Dicerna Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
RTW Investments LP
5,044,813
9.52%
15,351
4.59%
06/30/2018
RA Capital Management LLC
3,933,489
7.43%
0
3.44%
06/30/2018
Cormorant Asset Management LP
3,600,954
6.8%
0
4.03%
06/30/2018
Bridger Management LLC
3,225,527
6.09%
1,998,707
2.44%
06/30/2018
Ecor1 Capital LLC
2,961,147
5.59%
-1,803,300
4.88%
06/30/2018
Adage Capital Management LP
2,450,000
4.63%
725,000
0.08%
06/30/2018
BlackRock Fund Advisors
2,381,300
4.5%
2,107,586
0%
06/30/2018
Citadel Advisors LLC
1,712,315
3.23%
1,541,574
0.04%
06/30/2018
Fidelity Management & Research Co.
1,443,911
2.73%
-264,100
0%
06/30/2018
The Vanguard Group, Inc.
1,326,482
2.5%
102,273
0%
06/30/2018

About Dicerna Pharmaceuticals

View Profile
Address
87 Cambridgepark Drive
Cambridge Massachusetts 02140
United States
Employees -
Website http://www.dicerna.com
Updated 07/08/2019
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases using its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.